CNTY-813 Preclinical Data Shows Durable Glucose Control, Immune Evasion for Type 1 Diabetes
Summary
Century Therapeutics presented strong new preclinical data for its lead Type 1 Diabetes candidate, CNTY-813, at the ADA 2026 conference. The data demonstrated durable glucose control for over eight months in diabetic mice, effective immune evasion under alloimmune pressure, and scalable manufacturing without evidence of tumorigenesis. These results are critical for de-risking CNTY-813, which aims to be a functional cure for T1D without the need for chronic immunosuppression. This positive development follows recent capital raising activities, including a $126.4 million private placement and an ATM offering, which extended the company's cash runway. The company plans to submit an IND for CNTY-813 in Q4 2026, with initial clinical data anticipated in the second half of 2027.
At the time of this announcement, IPSC was trading at $2.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $382.4M. The 52-week trading range was $0.44 to $3.04. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.